Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 15/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 8/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 6/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30832969 | 1.00 | HDAC3 (0.66) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL25248640 | 0.86 | HDAC3 (0.72) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL8619629 | 0.86 | MAPK1 (0.60) | MAPK1NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL11719473 | 0.85 | HDAC3 (0.72) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| Hydrochloric Acid SCHEMBL8957362 | 0.84 | HDAC3 (0.70) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL27599377 | 0.83 | HDAC3 (0.64) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL7789440 | 0.82 | HDAC1 (0.79) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL16329196 | 0.82 | HDAC3 (0.68) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL29209745 | 0.82 | ALDH1A1 (0.51) | HDAC3HDAC1HDAC2HDAC10HDAC6 | |
| SCHEMBL27736940 | 0.82 | HDAC3 (0.78) | HDAC3HDAC1HDAC2HDAC10HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981665-B2 | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | CHEN ZHIHONG (US) | 2024-05-14 | — | — | US | disclosed |
| CN-111683662-B | Substituted pyrimidine compounds, pharmaceutical compositions and methods of treatment | 陈志宏 | 2024-04-02 | — | — | CN | disclosed |
| US-20230109688-A1 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | CHEN ZHIHONG (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3675860-B1 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | ZHIHONG CHEN (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11440904-B2 | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | CHEN ZHIHONG (US) | 2022-09-13 | — | — | US | disclosed |
| EP-3154954-B1 | METABOTROPIC GLUTAMATE RECEPTOR NEGATIVE ALLOSTERIC MODULATORS (NAMS) AND USES THEREOF | SANFORD BURNHAM MED RES INST (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3400210-B1 | \"MULTI-TARGET\" COMPOUNDS WITH INHIBITORY ACTIVITY TOWARDS HISTONE DEACETYLASES AND TUBULIN POLYMERISATION, FOR USE IN THE TREATMENT OF CANCER | UNIV PARIS SACLAY (FR) | 2021-09-29 | — | — | EP | disclosed |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-11014871-B2 | “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-05-25 | — | — | US | disclosed |
| CN-111683662-A | Substituted pyrimidines, pharmaceutical compositions and methods of treatment | 陈志宏 | 2020-09-18 | — | — | CN | disclosed |
| US-4757136-A | Water-soluble Azo compounds containing fiber-reactive groups and having a sulfo-naphthol coupling component with a triazinylamino substituent suitable as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-07-12 | — | — | US | disclosed |
| US-4740592-A | Water-soluble azo compounds containing fiber-reactive groups and having a sulfo-naphthal coupling component with a triazinylamino substituent suitable as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-04-26 | — | — | US | disclosed |
| EP-0218131-A1 | Water soluble azo compounds, process for their preparation and their use as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-15 | — | — | EP | disclosed |
| US-4220586-A | FASTNESS TO LIGHT, OVER-LACQUERING, MIGRATION, WEATHERING, AND HEAT | CIBA-GEIGY CORPORATION (US) | 1980-09-02 | — | — | US | disclosed |
| US-4062838-A | LACQUERS, PRINTING INKS, YELLOW TO ORANGE | CIBA-GEIGY CORPORATION (US) | 1977-12-13 | — | — | US | disclosed |
| US-4018814-A | ANTHELMINTICS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-04-19 | — | — | US | disclosed |
| US-4013676-A | NEMATOCIDES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-22 | — | — | US | disclosed |
| US-3996247-A | ANTHELMINTIC | BAYER AKTIENGESELLSCHAFT (DT) | 1976-12-07 | — | — | US | disclosed |
| US-3965087-A | Trisazo dye containing a diphenylenesulfone structure | SAKAI CHEMICAL INDUSTRY COMPANY LTD. (JA) | 1976-06-22 | — | — | US | disclosed |
| US-3951941-A | POLYAZODYE | SAKAI CHEMICAL INDUSTRY COMPANY, LIMITED (JA) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | BRD4, BET1, BRD3 | HDAC3 418/4885HDAC1 228/4885HDAC2 293/4885 |
| US-20230109688-A1 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | BTK, PTK2, LCK | HDAC3 2190/4885HDAC1 2735/4885HDAC2 1615/4885 |
| US-11981665-B2 | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | BTK, PTK2, LCK | HDAC3 2190/4885HDAC1 2735/4885HDAC2 1615/4885 |
| US-11440904-B2 | Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof | BTK, PTK2, LCK | HDAC3 2190/4885HDAC1 2735/4885HDAC2 1615/4885 |
| US-11014871-B2 | “Multi-target” compounds with inhibitory activity towards histone deacetylases and tubulin polymerisation, for use in the treatment of cancer | HDAC6, HDAC1, HDAC5 | HDAC3 6/4885HDAC1 2/4885HDAC2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.